September 21, 2021 Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
August 5, 2021 Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET
August 3, 2021 Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital
July 28, 2021 Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021
June 29, 2021 Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial
May 5, 2021 Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results
April 28, 2021 Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021
April 14, 2021 Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
April 1, 2021 Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase
